43
total announcements
500672.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 04 Oct 2026
Market Cap
₹4,837 Cr
P/E (TTM)
49.5
EPS (TTM)
₹39.55
52W Low
₹750.00
52W High
₹2,588.00
Dividend Yield
1.47%
Beta
0.32
Price / Book
5.9
Debt / Equity
0.4
Revenue (TTM)
₹371 Cr
Gross Margin
44.07%
Operating Margin
33.22%
Novartis India Ltd
Novartis India Ltd has completed the dispatch of the Notice of Postal Ballot (02/2026-27) to its members, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Novartis India Ltd
Novartis India Ltd (now Evonile Pharma Ltd) has announced a postal ballot to seek member consent for two special resolutions: granting employee stock options and creating a charge on the company's assets.
Novartis India Ltd
Novartis India Ltd has received a certificate from the Registrar to the Issue and Share Transfer Agent (RTA) for the quarter and half year ended September 30, 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
Novartis India Ltd
Novartis India Ltd, now known as Evonile Pharma Limited, has approved a rights issue to raise up to ₹9,000 million. The company has also constituted a Rights Issue Committee and approved the adoption and launch of its new corporate website.
Novartis India Ltd
Novartis India Ltd, now known as Evonile Pharma Limited, has approved a rights issue to raise up to ₹9,000 million through the issuance of partly paid-up equity shares. The company has also formed a Rights Issue Committee and approved the adoption of a new corporate website.
Novartis India Ltd
Novartis India Ltd, now known as Evonile Pharma Limited, has announced the outcome of its board meeting held on October 08, 2026. The board has approved the raising of funds through a rights issue, the constitution of a rights issue committee, the approval of a postal ballot notice, and the adoption and launch of the company's new corporate website.
Novartis India Ltd
Novartis India Ltd (formerly Evonile Pharma Ltd) has received credit ratings from CARE Ratings Limited for its bank facilities, with a long-term rating of CARE A and a short-term rating of CARE A2+.
Novartis India Ltd
Novartis India Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 08/10/2026 to consider raising funds through a rights issue.
Novartis India Ltd
Novartis India Ltd has announced the change in its name from 'Novartis India Limited' to 'Evonile Pharma Limited' effective October 1, 2026, following a Special Resolution passed at the 78th Annual General Meeting on September 24, 2026. The company has also amended its Memorandum and Articles of Association to reflect the new name.
Novartis India Ltd
Novartis India Ltd has changed its name to Evonile Pharma Limited, as per a fresh Certificate of Incorporation issued by the Ministry of Corporate Affairs, effective October 1, 2026.
Novartis India Ltd
Novartis India Ltd has scheduled a Board Meeting on 03/11/2026 to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Novartis India Ltd
Novartis India Ltd has announced the closure of its trading window for dealing in its securities, effective from October 01, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter and half year ended September 30, 2026.
Novartis India Ltd
Novartis India Ltd has announced the voting results and scrutinizer's report for its 78th Annual General Meeting (AGM) held on September 24, 2026. The company has received approval for the audited balance sheet and statement of profit and loss for the financial year ended March 31, 2026, as well as the appointment of Mr. Ashok Bhatia as a Non-Executive Director.
Novartis India Ltd
Novartis India Ltd held its 78th Annual General Meeting (AGM) on September 24, 2026, through video conferencing. The meeting was attended by all independent directors, the managing director, and other key officials. The shareholders approved the audited balance sheet and statement of profit and loss for the financial year ended March 31, 2026. The meeting also regularized the appointments of four additional non-executive directors.
Novartis India Ltd
Novartis India Ltd has informed BSE that officials will participate in the Emerging India CEO Forum on September 28, 2026, without disclosing any unpublished price sensitive information.
Novartis India Ltd
Novartis India Ltd has announced the transcript of the Analysts/Institutional Investors Call held on September 11, 2026, as per Regulation 30 of the SEBI Listing Regulations.
Novartis India Ltd
Novartis India Ltd has scheduled an Investor / Analyst Call on September 11, 2026, to discuss publicly available information.
Novartis India Ltd
Novartis India Ltd has published a newspaper advertisement in Financial Express and Navshakti regarding the completion of sending the notice of the 78th Annual General Meeting (AGM) along with the Annual Report for the financial year 2025-26 to the members of the company.
Novartis India Ltd
Novartis India Ltd has submitted its Annual Report for FY 2025-26, along with the Notice of 78th AGM, to the BSE. The report is available on the company's website. The AGM will be held on September 24, 2026, through video conferencing.
Novartis India Ltd
Novartis India Ltd has announced the notice of its 78th Annual General Meeting (AGM) to be held on September 24, 2026, through video conferencing. The company has also submitted its annual report for the financial year 2025-26, which includes the notice of the AGM.